PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 1992 October; 36(10): 2192–2196.
PMCID: PMC245474

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Abstract

A prospective, randomized study comparing oral teicoplanin with oral vancomycin in the treatment of pseudomembranous colitis (PMC) and Clostridium difficile-associated diarrhea (CDAD) was performed. Teicoplanin was administered at a dosage of 100 mg twice a day for 10 days, and vancomycin was administered at a dosage of 500 mg four times a day for 10 days. CDAD was diagnosed by demonstrating both C. difficile and cytotoxin in the feces of symptomatic patients (more than three loose stools per day). The diagnosis of PMC was also based on colonoscopy. Cytotoxin assay and cultures were checked in all patients 7 to 10 days after discontinuation of therapy and 25 to 30 days thereafter. Of the 51 patients enrolled, 46 were judged to be assessable. Among these, 26 received teicoplanin and 20 received vancomycin. At enrollment, both groups were comparable in terms of age, sex, occurrence of PMC or CDAD, and previous antibiotic treatment. Eighteen of the 20 patients in the vancomycin group and 10 of the 26 patients in the teicoplanin group had previously undergone surgery (P = 0.0004). Treatment resulted in the clinical cure of 20 (100%) vancomycin and 25 (96.2%) teicoplanin patients (P = 0.56). After discontinuation of therapy, clinical symptoms recurred in four (20%) vancomycin patients and two (7.7%) teicoplanin patients (P = 0.21). Posttherapy asymptomatic C. difficile carriage (positive follow-up cultures without any clinical symptoms) occurred in five (25%) vancomycin patients and two (7.7%) teicoplanin patients (P = 0.11).Overall, 9 of 20 (45%) vancomycin patients and 5 of 26 (19.2%) teicoplanin patients (P=0.059) appeared not to be cleared of C. difficile after treatment. No adverse effects related to vancomycin or teicoplanin therapy were observed.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology. 1980 Mar;78(3):431–434. [PubMed]
  • Bender BS, Bennett R, Laughon BE, Greenough WB, 3rd, Gaydos C, Sears SD, Forman MS, Bartlett JG. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986 Jul 5;2(8497):11–13. [PubMed]
  • Biavasco F, Manso E, Varaldo PE. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1991 Jan;35(1):195–197. [PMC free article] [PubMed]
  • Buchanan AG. Selective enrichment broth culture for detection of Clostridium difficile and associated cytotoxin. J Clin Microbiol. 1984 Jul;20(1):74–76. [PMC free article] [PubMed]
  • Clabots CR, Peterson LR, Gerding DN. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. J Infect Dis. 1988 Oct;158(4):731–736. [PubMed]
  • Corti A, Cavenaghi L, Giani E, Cassani G. A receptor-antibody sandwich assay for teicoplanin. Clin Chem. 1987 Sep;33(9):1615–1618. [PubMed]
  • Cumming AD, Thomson BJ, Sharp J, Poxton IR, Fraser A. Diarrhoea due to Clostridium difficile associated with antibiotic treatment in patients receiving dialysis: the role of cross infection. Br Med J (Clin Res Ed) 1986 Jan 25;292(6515):238–239. [PMC free article] [PubMed]
  • de Lalla F, Privitera G, Rinaldi E, Ortisi G, Santoro D, Rizzardini G. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother. 1989 Jul;33(7):1125–1127. [PMC free article] [PubMed]
  • de Lalla F, Santoro D, Rinaldi E, Suter F, Cruciani M, Guaglianone MH, Rizzardini G, Pellegata G. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria. J Antimicrob Chemother. 1989 Jan;23(1):131–142. [PubMed]
  • Delmee M, Bulliard G, Simon G. Application of a technique for serogrouping Clostridium difficile in an outbreak of antibiotic-associated diarrhoea. J Infect. 1986 Jul;13(1):5–9. [PubMed]
  • Delmee M, Homel M, Wauters G. Serogrouping of Clostridium difficile strains by slide agglutination. J Clin Microbiol. 1985 Mar;21(3):323–327. [PMC free article] [PubMed]
  • Delmée M, Vandercam B, Avesani V, Michaux JL. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol. 1987 Dec;6(6):623–627. [PubMed]
  • Fekety R. Recent advances in management of bacterial diarrhea. Rev Infect Dis. 1983 Mar-Apr;5(2):246–257. [PubMed]
  • Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J., Jr Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med. 1981 Apr;70(4):906–908. [PubMed]
  • Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):97–102. [PubMed]
  • Fekety R, Silva J, Toshniwal R, Allo M, Armstrong J, Browne R, Ebright J, Rifkin G. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis. 1979 Mar-Apr;1(2):386–397. [PubMed]
  • George WL. Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S208–S213. [PubMed]
  • Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989 Feb 15;110(4):255–257. [PubMed]
  • Heard SR, O'Farrell S, Holland D, Crook S, Barnett MJ, Tabaqchali S. The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J Infect Dis. 1986 Jan;153(1):159–162. [PubMed]
  • Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GA. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J. 1978 Dec 16;2(6153):1667–1669. [PMC free article] [PubMed]
  • Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J, Jr, Waters D. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981 Jan;143(1):42–50. [PubMed]
  • Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988 Jan;1(1):1–18. [PMC free article] [PubMed]
  • Malamou-Ladas H, O'Farrell S, Nash JQ, Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol. 1983 Jan;36(1):88–92. [PMC free article] [PubMed]
  • McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989 Jan 26;320(4):204–210. [PubMed]
  • Mulligan ME, George WL, Rolfe RD, Finegold SM. Epidemiological aspects of Clostridium difficile-induced diarrhea and colitis. Am J Clin Nutr. 1980 Nov;33(11 Suppl):2533–2538. [PubMed]
  • Newsom SW, Matthews J, Rampling AM. Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem. J Antimicrob Chemother. 1985 May;15(5):648–649. [PubMed]
  • Pantosti A, Luzzi I, Cardines R, Gianfrilli P. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine. Antimicrob Agents Chemother. 1985 Dec;28(6):847–848. [PMC free article] [PubMed]
  • Siegel DL, Edelstein PH, Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA. 1990 Feb 16;263(7):979–982. [PubMed]
  • Silva J, Jr, Batts DH, Fekety R, Plouffe JF, Rifkin GD, Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med. 1981 Nov;71(5):815–822. [PubMed]
  • Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother. 1991 Jun;35(6):1108–1111. [PMC free article] [PubMed]
  • Tabaqchali S, Holland D, O'Farrell S, Silman R. Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies. Lancet. 1984 Apr 28;1(8383):935–938. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)